Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Revenue (2016 - 2025)

Historic Revenue for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $205.7 million.

  • Myriad Genetics' Revenue fell 356.31% to $205.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $825.3 million, marking a year-over-year increase of 20.64%. This contributed to the annual value of $837.6 million for FY2024, which is 1120.55% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Revenue is $205.7 million, which was down 356.31% from $213.1 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Revenue high stood at $213.3 million for Q3 2024, and its period low was $156.4 million during Q3 2022.
  • Its 5-year average for Revenue is $188.1 million, with a median of $189.4 million in 2021.
  • Over the last 5 years, Myriad Genetics' Revenue had its largest YoY gain of 10321.89% in 2021, and its largest YoY loss of 4636.42% in 2021.
  • Over the past 5 years, Myriad Genetics' Revenue (Quarter) stood at $160.8 million in 2021, then increased by 10.57% to $177.8 million in 2022, then rose by 10.57% to $196.6 million in 2023, then grew by 7.12% to $210.6 million in 2024, then decreased by 2.33% to $205.7 million in 2025.
  • Its Revenue was $205.7 million in Q3 2025, compared to $213.1 million in Q2 2025 and $195.9 million in Q1 2025.